Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, "Toripalimab has made significant strides in its ...

A Keighley deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.

UroGen Pharma Ltd., a pioneering pharmaceutical company with a focus on innovative treatments for urothelial cancers, recently submitted an 8-K form to the Securities and Exchange Commission, ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time ...

BladderPath trial found that patients with suspected invasive bladder cancer undergoing initial mpMRI were treated faster ...

In December 2024, BioNTech initiated a global randomized Phase 3 clinical trial ( NCT06712355) evaluating BNT327/PM8002 plus chemotherapy compared to atezolizumab plus chemotherapy in first line ...